Primary prevention of cardiovascular disease through community pharmacist management of multiple risk factors

Phase 2

Completed

• Conditions: Cardiovascular disease risk; Cardiovascular - Normal development and function of the cardiovascular system

• Registration Number: ACTRN12609000677202
• Lead Sponsor: Monash University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-08-10
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Patients aged 50-74 years, taking one or more medicines for cholesterol or hypertension, and without established cardiovascular disease or a cardiovascular event

Exclusion Criteria

1. patients with a complex debilitating coexisting medical condition (e.g. mental illness, end-stage cancer)
2. Previously-identified diabetes
3. Target organ damage
4. Any cognitive impairment
5. Dependent patients relying on a carer or living in a residential aged care facility
6. Recent hospital inpatients who were medical admissions and discharged less than four weeks prior to recruitment
7. Non-English speaking
8. Living more than 40 km from a participating pharmacy
9. Patients who have received a Home Medication Review (HMR) in the past 12 months
10. Patients whose GP has deemed them inappropriate for this intervention
Patients of GPs who express a desire not to have any involvement with this project

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change to risk of cardiovascular disease (as per New Zealand risk calculations)[At six months from the baseline timepoint for each individual patient]

Secondary Outcome Measures

Name	Time	Method
Change to patient health behaviour. Issues around medication adherence, physical activity, smoking, nutrition, weight management, quality of life and alcohol consumption will be measured using survey instruments administered by researchers.[At six months from the baseline timepoint for each individual patient];Change to individual cardiovascular risk factors. Blood pressure, lipid profile, random blood glucose, waist, hip and body mass index (BMI) will be measured using point of care testing equipment. Depression will be self-reported by administration of the Center for Epidemiologic Studies Depression (CES D ) 10 item survey scale.[At six months from the baseline timepoint for each individual patient]